Key result
The use of the oral contraceptive norethynodrel with ethynylestradiol 3-methyl ether (Enovid) was temporally associated with massive thromboembolism in a patient case.
Why the study?
Is the use of norethynodrel with ethynylestradiol 3-methyl ether associated with thromboembolic disease?
Case Report (n=1)
Is the use of norethynodrel with ethynylestradiol 3-methyl ether associated with thromboembolic disease?
This early report highlights a potential association between oral contraceptives containing norethynodrel and massive thromboembolism.
No takes yet. Share an insight, caveat, or question.
Case report leaves open possible Enovid-thromboembolism link; no practice change warranted without systematic confirmation.
Minogue et al. (1963) conducted a case report in Thromboembolic disease (n=1). Norethynodrel with ethynylestradiol 3-methyl ether (Enovid) was evaluated on Massive thromboembolism. The use of the oral contraceptive norethynodrel with ethynylestradiol 3-methyl ether (Enovid) was temporally associated with massive thromboembolism in a patient case.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: